New online program aims to ease anxiety for parents of kids with rare diseases

NCT ID NCT06548022

Completed Symptom relief Sponsor: Children's National Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a 5-week online group program called Rare Group Problem Management Plus (PM+) for parents of children with rare diseases. The program teaches stress management and problem-solving skills to help reduce anxiety, depression, and distress. Eight parents participated, and the study measured how many stayed in the program to see if it was acceptable and helpful.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rare Group Problem Management Plus (Group PM+)
What this could lead to: If it works, this could offer a practical, online way to reduce stress and anxiety for parents caring for children with rare diseases.
What could go wrong: This is a very small, completed study with only 8 participants and no control group, so results may not apply to all caregivers. The program is behavioral, not a medical treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder Depression post-traumatic stress disorder Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANXIETY DEPRESSIVE SYMPTOMS POST-TRAUMATIC STRESS DISORDER PROBLEMS PSYCHOSOCIAL

Contacts and locations

Locations

Children's National Hospital

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.